Clinical Trials Logo

Anxiety Disorder Generalized clinical trials

View clinical trials related to Anxiety Disorder Generalized.

Filter by:
  • None
  • Page 1

NCT ID: NCT05549102 Recruiting - Anxiety Clinical Trials

CBT and the Neural Circuits of Anxiety

Start date: February 2, 2020
Phase:
Study type: Observational

This study will aim to test whether specific neural circuitry changes, proposed on the basis of a neurocognitive model of anxiety, are a mechanism of action for Cognitive Behavioural Therapy (CBT) interventions. This study aims to provide a theoretical model of the neurobiological mechanisms of CBT's therapeutic effect, where there currently is none, and potentially allow for more targeted/specific approaches to anxiety disorders following the identification of key CBT mechanisms. The ultimate aim is to improve the efficacy of CBT, and more generally, psychological interventions for anxiety disorders.

NCT ID: NCT04598867 Not yet recruiting - Clinical trials for Anxiety Disorder Generalized

A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Start date: December 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo- and active-controlled study to assess the efficacy and safety of CD-008-0045 in patients with generalized anxiety disorder (GAD). Each patient will participate in the study for the period of approximately 37 weeks: Screening and Run-in period: 1 week; Study Treatment period: 32 weeks; Follow-up period: 4 weeks.

NCT ID: NCT04524975 Completed - Clinical trials for Anxiety Disorder Generalized

А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Start date: October 2, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding pilot study to assess the efficacy and safety of CD-008-0045 in patients with Generalized Anxiety Disorder (GAD). Each patient will participate in the study for the period of approximately 10 weeks: Screening and Run-in period: 1 week; Study Treatment period: 8 weeks; Follow-up period: 1 week.